Form D · Biotechnology
Variation Biotechnologies (US), Inc.
Cambridge, MA · CIK 0001525594
Offering snapshot reported Mar 25, 2014 · SEC filing
- Reported sold
- $1.5M Offering amount: $1.5M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 10, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 25, 2014 | Initial | $1,500,000 | No comparison | 8 | SEC filing |
| Dec 24, 2013 | Initial | $1,375,000 | No comparison | 2 | SEC filing |
| Sep 10, 2013 | Initial | $250,000 | No comparison | 2 | SEC filing |
| Jun 20, 2013 | Initial | $750,000 | No comparison | 2 | SEC filing |
| Mar 8, 2013 | Initial | $751,061 | No comparison | 4 | SEC filing |
| Nov 9, 2012 | Initial | $1,200,000 | No comparison | 4 | SEC filing |
| Jun 29, 2012 | Initial | $1,200,000 | No comparison | 4 | SEC filing |
| Feb 10, 2012 | Initial | $2,200,000 | No comparison | 4 | SEC filing |
| Jul 15, 2011 | Initial | $4,331,932 | No comparison | 4 | SEC filing |
| Jul 15, 2011 | Initial | $3,500,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $65K
- Finders' fees
- $0
- Form D file number
- 021-214214
Middlebury and Palladium received 6% and 7%, for their $500K placements, respectively.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Middlebury Securities, LLC | 122602 | Middlebury Securities, LLC · CRD 122602 |
| Palladium Capital Advisors, LLC | 129400 | Palladium Capital Advisors, LLC · CRD 129400 |
Source: Form D, filed Mar 25, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David E. Anderson | Executive |
| Jeff Baxter | Director, Executive |
| Adam Buckley | Executive |
| Kevin Forrest | Director |
| Stephen Gillis | Director |
| Steven Gillis | Director |
| Steve Gillis | Director |
| Marc J. Kirchmeier | Executive |
| Jeffrey Leiden | Director |
| Egidio Nascimento | Executive |
| Scott Rocklage | Director |
| Michael Steinmetz | Director |
| Steven Vignau | Director |
| Steve Vignau | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
222 3 Rd Street Suite 2241
Cambridge, MA, 02142
Cambridge, MA, 02142